NCT00721812View on ClinicalTrials.gov

A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686

PHASE1CompletedINTERVENTIONAL

Enrollment

87

Participants

Timeline

Start Date

September 25, 2008

Primary Completion Date

May 27, 2009

Study Completion Date

May 27, 2009

Conditions

Inflammatory Bowel Diseases

Interventions

DRUG

GSK1399686

Safety and tolerability dose escalation in normal human volunteers

Trial Locations (1)

HA1 3UJ

GSK Investigational Site, Harrow

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY